Ontology type: schema:ScholarlyArticle Open Access: True
2012-11-06
AUTHORSE Jabbour, P D le Coutre, J Cortes, F Giles, K N Bhalla, J Pinilla-Ibarz, R A Larson, N Gattermann, O G Ottmann, A Hochhaus, T P Hughes, G Saglio, J P Radich, D-W Kim, G Martinelli, J Reynolds, R C Woodman, M Baccarani, H M Kantarjian
ABSTRACTThe purpose was to assess predictive factors for outcome in patients with chronic myeloid leukemia (CML) in chronic phase (CML-CP) treated with nilotinib after imatinib failure. Imatinib-resistant and -intolerant patients with CML-CP (n=321) were treated with nilotinib 400 mg twice daily. Of 19 baseline patient and disease characteristics and two response end points analyzed, 10 independent prognostic factors were associated with progression-free survival (PFS). In the multivariate analysis, major cytogenetic response (MCyR) within 12 months, baseline hemoglobin ⩾120 g/l, baseline basophils <4%, and absence of baseline mutations with low sensitivity to nilotinib were associated with PFS. A prognostic score was created to stratify patients into five groups (best group: 0 of 3 unfavorable risk factors and MCyR by 12 months; worst group: 3 of 3 unfavorable risk factors and no MCyR by 12 months). Estimated 24-month PFS rates were 90%, 79%, 67% and 37% for patients with prognostic scores of 0, 1, 2 and 3, respectively, (no patients with score of 4). Even in the presence of poor disease characteristics, nilotinib provided significant clinical benefit in patients with imatinib-resistant or -intolerant CML. This system may yield insight on the prognosis of patients. More... »
PAGES907-913
http://scigraph.springernature.com/pub.10.1038/leu.2012.305
DOIhttp://dx.doi.org/10.1038/leu.2012.305
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1022553509
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/23174881
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Cardiorespiratory Medicine and Haematology",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Adult",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Aged",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Aged, 80 and over",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Antineoplastic Agents",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Benzamides",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Drug Resistance, Neoplasm",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Female",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Humans",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Imatinib Mesylate",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Leukemia, Myelogenous, Chronic, BCR-ABL Positive",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Male",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Middle Aged",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Multivariate Analysis",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Piperazines",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Prognosis",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Pyrimidines",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Young Adult",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Department of Leukemia, MD Anderson Cancer Center, The University of Texas, Houston, TX, USA",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Department of Leukemia, MD Anderson Cancer Center, The University of Texas, Houston, TX, USA"
],
"type": "Organization"
},
"familyName": "Jabbour",
"givenName": "E",
"id": "sg:person.01231012673.12",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01231012673.12"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Medizinische Klinik m.S. H\u00e4matologie und Onkologie, Charit\u00e9\u2014University of Medicine Berlin, Berlin, Germany",
"id": "http://www.grid.ac/institutes/grid.6363.0",
"name": [
"Medizinische Klinik m.S. H\u00e4matologie und Onkologie, Charit\u00e9\u2014University of Medicine Berlin, Berlin, Germany"
],
"type": "Organization"
},
"familyName": "le Coutre",
"givenName": "P D",
"id": "sg:person.01344447222.75",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01344447222.75"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Leukemia, MD Anderson Cancer Center, The University of Texas, Houston, TX, USA",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Department of Leukemia, MD Anderson Cancer Center, The University of Texas, Houston, TX, USA"
],
"type": "Organization"
},
"familyName": "Cortes",
"givenName": "J",
"id": "sg:person.016160407152.27",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016160407152.27"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "HRB Clinical Research Facility, National University of Ireland Galway and Trinity College Dublin, Galway, Ireland",
"id": "http://www.grid.ac/institutes/None",
"name": [
"HRB Clinical Research Facility, National University of Ireland Galway and Trinity College Dublin, Galway, Ireland"
],
"type": "Organization"
},
"familyName": "Giles",
"givenName": "F",
"id": "sg:person.010046107662.90",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010046107662.90"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Kansas University Medical Center, University of Kansas Cancer Center, Kansas City, KS, USA",
"id": "http://www.grid.ac/institutes/grid.412016.0",
"name": [
"Kansas University Medical Center, University of Kansas Cancer Center, Kansas City, KS, USA"
],
"type": "Organization"
},
"familyName": "Bhalla",
"givenName": "K N",
"id": "sg:person.0576206246.42",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0576206246.42"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Malignant Hematology Division, H Lee Moffitt Cancer Center, Tampa, FL, USA",
"id": "http://www.grid.ac/institutes/grid.468198.a",
"name": [
"Malignant Hematology Division, H Lee Moffitt Cancer Center, Tampa, FL, USA"
],
"type": "Organization"
},
"familyName": "Pinilla-Ibarz",
"givenName": "J",
"id": "sg:person.01214300454.43",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01214300454.43"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "University of Chicago, Chicago, IL, USA",
"id": "http://www.grid.ac/institutes/grid.170205.1",
"name": [
"University of Chicago, Chicago, IL, USA"
],
"type": "Organization"
},
"familyName": "Larson",
"givenName": "R A",
"id": "sg:person.011155432117.78",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011155432117.78"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Heinrich-Heine-Universitat, D\u00fcsseldorf, Germany",
"id": "http://www.grid.ac/institutes/grid.411327.2",
"name": [
"Heinrich-Heine-Universitat, D\u00fcsseldorf, Germany"
],
"type": "Organization"
},
"familyName": "Gattermann",
"givenName": "N",
"id": "sg:person.01273447501.34",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01273447501.34"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Medizinische Klinik II - Johann Wolfgang Goethe-University, Frankfurt, Germany",
"id": "http://www.grid.ac/institutes/grid.7839.5",
"name": [
"Medizinische Klinik II - Johann Wolfgang Goethe-University, Frankfurt, Germany"
],
"type": "Organization"
},
"familyName": "Ottmann",
"givenName": "O G",
"id": "sg:person.01051501512.14",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01051501512.14"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Abteilung H\u00e4matologie/Onkologie, Klinik f\u00fcr Innere Medizin II, Universit\u00e4tsklinikum Jena, Jena, Germany",
"id": "http://www.grid.ac/institutes/grid.275559.9",
"name": [
"Abteilung H\u00e4matologie/Onkologie, Klinik f\u00fcr Innere Medizin II, Universit\u00e4tsklinikum Jena, Jena, Germany"
],
"type": "Organization"
},
"familyName": "Hochhaus",
"givenName": "A",
"id": "sg:person.01064615503.48",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01064615503.48"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Royal Adelaide Hospital, SA Pathology, Adelaide, South Australia, Australia",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Royal Adelaide Hospital, SA Pathology, Adelaide, South Australia, Australia"
],
"type": "Organization"
},
"familyName": "Hughes",
"givenName": "T P",
"id": "sg:person.014243130677.65",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014243130677.65"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Division of Internal Medicine & Hematology, University of Turin, Orbassano, Italy",
"id": "http://www.grid.ac/institutes/grid.7605.4",
"name": [
"Division of Internal Medicine & Hematology, University of Turin, Orbassano, Italy"
],
"type": "Organization"
},
"familyName": "Saglio",
"givenName": "G",
"id": "sg:person.01334477453.06",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01334477453.06"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA",
"id": "http://www.grid.ac/institutes/grid.270240.3",
"name": [
"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA"
],
"type": "Organization"
},
"familyName": "Radich",
"givenName": "J P",
"id": "sg:person.011362420057.85",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011362420057.85"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Seoul St Mary\u2019s Hospital, The Catholic University of Korea, Seoul, South Korea",
"id": "http://www.grid.ac/institutes/grid.414966.8",
"name": [
"Seoul St Mary\u2019s Hospital, The Catholic University of Korea, Seoul, South Korea"
],
"type": "Organization"
},
"familyName": "Kim",
"givenName": "D-W",
"id": "sg:person.013164724220.98",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013164724220.98"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Institute of Hematology \u201cL. e A. Ser\u00e0gnoli\u201d, University of Bologna, Bologna, Italy",
"id": "http://www.grid.ac/institutes/grid.6292.f",
"name": [
"Institute of Hematology \u201cL. e A. Ser\u00e0gnoli\u201d, University of Bologna, Bologna, Italy"
],
"type": "Organization"
},
"familyName": "Martinelli",
"givenName": "G",
"id": "sg:person.012171410322.93",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012171410322.93"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Novartis Pharma AG, Basel, Switzerland",
"id": "http://www.grid.ac/institutes/grid.419481.1",
"name": [
"Novartis Pharma AG, Basel, Switzerland"
],
"type": "Organization"
},
"familyName": "Reynolds",
"givenName": "J",
"id": "sg:person.0716734224.06",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0716734224.06"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA",
"id": "http://www.grid.ac/institutes/grid.418424.f",
"name": [
"Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA"
],
"type": "Organization"
},
"familyName": "Woodman",
"givenName": "R C",
"id": "sg:person.0755570025.09",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0755570025.09"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Institute of Hematology \u201cL. e A. Ser\u00e0gnoli\u201d, University of Bologna, Bologna, Italy",
"id": "http://www.grid.ac/institutes/grid.6292.f",
"name": [
"Institute of Hematology \u201cL. e A. Ser\u00e0gnoli\u201d, University of Bologna, Bologna, Italy"
],
"type": "Organization"
},
"familyName": "Baccarani",
"givenName": "M",
"id": "sg:person.01016466503.33",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01016466503.33"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Leukemia, MD Anderson Cancer Center, The University of Texas, Houston, TX, USA",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Department of Leukemia, MD Anderson Cancer Center, The University of Texas, Houston, TX, USA"
],
"type": "Organization"
},
"familyName": "Kantarjian",
"givenName": "H M",
"id": "sg:person.07607502677.73",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07607502677.73"
],
"type": "Person"
}
],
"datePublished": "2012-11-06",
"datePublishedReg": "2012-11-06",
"description": "The purpose was to assess predictive factors for outcome in patients with chronic myeloid leukemia (CML) in chronic phase (CML-CP) treated with nilotinib after imatinib failure. Imatinib-resistant and -intolerant patients with CML-CP (n=321) were treated with nilotinib 400\u2009mg twice daily. Of 19 baseline patient and disease characteristics and two response end points analyzed, 10 independent prognostic factors were associated with progression-free survival (PFS). In the multivariate analysis, major cytogenetic response (MCyR) within 12 months, baseline hemoglobin \u2a7e120\u2009g/l, baseline basophils <4%, and absence of baseline mutations with low sensitivity to nilotinib were associated with PFS. A prognostic score was created to stratify patients into five groups (best group: 0 of 3 unfavorable risk factors and MCyR by 12 months; worst group: 3 of 3 unfavorable risk factors and no MCyR by 12 months). Estimated 24-month PFS rates were 90%, 79%, 67% and 37% for patients with prognostic scores of 0, 1, 2 and 3, respectively, (no patients with score of 4). Even in the presence of poor disease characteristics, nilotinib provided significant clinical benefit in patients with imatinib-resistant or -intolerant CML. This system may yield insight on the prognosis of patients.",
"genre": "article",
"id": "sg:pub.10.1038/leu.2012.305",
"isAccessibleForFree": true,
"isFundedItemOf": [
{
"id": "sg:grant.2438826",
"type": "MonetaryGrant"
}
],
"isPartOf": [
{
"id": "sg:journal.1097065",
"issn": [
"0887-6924",
"1476-5551"
],
"name": "Leukemia",
"publisher": "Springer Nature",
"type": "Periodical"
},
{
"issueNumber": "4",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "27"
}
],
"keywords": [
"chronic myeloid leukemia",
"progression-free survival",
"prognostic score",
"chronic phase",
"disease characteristics",
"myeloid leukemia",
"intolerant chronic myeloid leukemia",
"resistance/intolerance",
"major cytogenetic response",
"independent prognostic factor",
"prognosis of patients",
"significant clinical benefit",
"response end points",
"prediction of outcome",
"imatinib failure",
"nilotinib 400",
"baseline hemoglobin",
"baseline basophils",
"PFS rates",
"CML-CP",
"baseline patient",
"intolerant patients",
"prognostic factors",
"baseline mutations",
"cytogenetic response",
"predictive factors",
"clinical benefit",
"patients",
"multivariate analysis",
"nilotinib",
"end point",
"leukemia",
"outcomes",
"scores",
"low sensitivity",
"prognosis",
"basophils",
"intolerance",
"months",
"hemoglobin",
"survival",
"factors",
"failure",
"group",
"mutations",
"response",
"absence",
"benefits",
"sensitivity",
"rate",
"presence",
"characteristics",
"purpose",
"analysis",
"phase",
"insights",
"point",
"system",
"prediction"
],
"name": "Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance",
"pagination": "907-913",
"productId": [
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1022553509"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1038/leu.2012.305"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"23174881"
]
}
],
"sameAs": [
"https://doi.org/10.1038/leu.2012.305",
"https://app.dimensions.ai/details/publication/pub.1022553509"
],
"sdDataset": "articles",
"sdDatePublished": "2022-08-04T17:00",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_575.jsonl",
"type": "ScholarlyArticle",
"url": "https://doi.org/10.1038/leu.2012.305"
}
]Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/leu.2012.305'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/leu.2012.305'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/leu.2012.305'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/leu.2012.305'
This table displays all metadata directly associated to this object as RDF triples.
359 TRIPLES
20 PREDICATES
101 URIs
93 LITERALS
24 BLANK NODES